FDAnews
www.fdanews.com/articles/120894-latisse-web-page-cited-in-fda-untitled-letter

Latisse Web Page Cited in FDA Untitled Letter

September 30, 2009
The FDA has warned Allergan for omitting and minimizing risks in web advertising for its prescription eyelash enhancer Latisse (bimatoprost). The company’s website fails to mention potential side effects like eye infections or excess hair growth, according to a Sept. 10 untitled letter posted recently to the agency’s website. The letter also notes the company did not properly present risk information in a timeline display exhibit, which Allergan said it is no longer using.
Washington Drug Letter